Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations: Application to Florida in 2000 through 2025

Burge, Russel; King, Alison B.; Balda, Eric; Worley, Dan

doi:10.1046/j.1524-4733.2003.65261.x

Cited by 44 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ziel ist es, eine ökonomische Basis für politische Entscheidungen und Behandlungsalternativen zur Verfügung zu stellen, in dem sie die Auswirkungen einer spezifischen Krankheit in einen volkswirtschaftlichen Rahmen setzen [7]. Einer validen Krankheitskostenschätzung der Osteoporose stehen jedoch in den meisten Ländern die Unterdiagnostizierung, fehlende Daten zu Langzeitfolgen von Brüchen und extramuraler Versorgung sowie mangelnde standardisierte Evaluationsmethoden entgegen [9,10] Kosten-Effektivitäts-Analyse (CEA) Eine zweite, weitverbreitete Methode ist die KostenEffektivitäts-Analyse (CEA). Ihr Ziel ist es, Behandlungsalternativen gegenüberzustellen, um die kosteneffektivste zu bestimmen.…”

Section: Krankheitskostenanalyseunclassified

Ökonomische Konzepte zur Erfassung der Krankheitskosten von Osteoporose: Österreich im internationalen Vergleich

Stein

Dörner

Lawrence

et al. 2009

Wien Med Wochenschr

View full text Add to dashboard Cite

Worldwide osteoporosis is underestimated and despite availability of effective and cost effective treatments, these are often not implemented. Apart from a demographically driven increase in disease cases, failure to implement or tardy implementation of preventive measures as well as poor treatment compliance leads to a deterioration of the health economic outcomes. This in turn causes considerable costs to the health care system and to society, through ineffective intake of medication, diminished quality of life and inability to work as well as substantial costs of rehabilitation of patients. Health economic analyses and methods are increasingly used by decision makers to set priorities and evaluate alternative treatment measures about their cost-effectiveness. In order to be able to capture the costs of illness incurred by osteoporosis, different diseases specific models and methods have been developed, such as the reference model of the IOF, an osteoporosis-specific Markov model or internationally comparable intervention thresholds. Health economists estimate that osteoporosis-related costs will double by 2050 in both Europe and the individual countries. For Europe this means an increase from 40 billion Euro in 2000 to almost 80 billion Euro in 2050. In Austria, an aggregation of the different costs of osteoporosis is not possible, due to a lack of comparability and availability of data. The international ICUROS study and the Austrian Osteoporosis Report 2007 are the first steps towards counteracting this situation.

show abstract

Section: Krankheitskostenanalyseunclassified

Ökonomische Konzepte zur Erfassung der Krankheitskosten von Osteoporose: Österreich im internationalen Vergleich

Stein

Dörner

Lawrence

et al. 2009

Wien Med Wochenschr

View full text Add to dashboard Cite

show abstract

“…(8) Given health care inflation and projected increases in fracture incidence, osteoporosisrelated direct and indirect costs are expected to double or triple over the next few decades. (8,9) Remarkable progress has been made in understanding the fundamental role of estrogen in maintaining bone homeostasis and the complex mechanisms by which estrogen deficiency contributes to bone loss. (10)(11)(12) Declining estrogen levels may be a principal cause of early and late phases of postmenopausal bone loss, albeit through different mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study

Miller

Chines²,

Christiansen

et al. 2008

Journal of Bone and Mineral Research

216

172

View full text Add to dashboard Cite

Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD.Introduction: Bazedoxifene is a novel selective estrogen receptor modulator that has increased BMD and bone strength in experimental models, without stimulating breast or uterus. This 24-mo, randomized, doubleblind study assessed the efficacy and safety of three doses of bazedoxifene compared with placebo and raloxifene in the prevention of postmenopausal osteoporosis. Materials and Methods: Healthy postmenopausal women with a BMD T-score at the lumbar spine or femoral neck between -1.0 and −2.5 or clinical risk factors for osteoporosis were randomly assigned to one of five groups: bazedoxifene 10, 20, or 40 mg/d, placebo, or raloxifene 60 mg/d. All women received elemental calcium. Efficacy outcomes included changes from baseline through 24 mo in BMD of the lumbar spine, hip, femoral neck, and femoral trochanter and biomarkers of bone metabolism. Results:The intent-to-treat population included 1434 women (mean age, 58 yr; mean time from last menstrual period, 11 yr). All doses of bazedoxifene and raloxifene prevented bone loss, whereas in the placebo group, there was significant loss of BMD at all skeletal sites. Mean differences in percent change in lumbar spine BMD from baseline to 24 mo relative to placebo were 1.08 ± 0.28%, 1.41 ± 0.28%, 1.49 ± 0.28%, and 1.49 ± 0.28% for 10, 20, and 40 mg bazedoxifene and 60 mg raloxifene, respectively (p < 0.001 for all comparisons). Comparable BMD responses were observed at other body sites. Significant and comparable decreases in serum osteocalcin and C-telopeptide levels from baseline and relative to placebo with active treatment were observed as early as 3 mo and were sustained through study conclusion (p < 0.001). Overall incidences of adverse events, serious adverse events, and discontinuations caused by adverse events were similar between groups. The most common adverse events included headache, infection, arthralgia, pain, hot flush, and back pain. Conclusions: Treatment with bazedoxifene prevented bone loss and reduced bone turnover equally as well as raloxifene and was generally well tolerated in postmenopausal women with normal/low BMD.

show abstract

“…Cohort studies involving primary data collection have been used to estimate osteoporosis prevalence [7,8], but such studies are expensive and time-consuming to conduct. Population-based administrative databases are increasingly being explored for their potential to provide epidemiological information (i.e., incidence, prevalence, geographic, and socioeconomic disparities) about osteoporosis [9][10][11][12][13][14] and other chronic diseases [15][16][17]. The advantages of using administrative data include: (a) it is relatively inexpensive to establish and maintain a population-based surveillance system using these databases, (b) longitudinal studies can be conducted using data linkage techniques, and (c) disease cases and non-cases can be compared on co-morbid conditions.…”

Section: Introductionmentioning

confidence: 99%

Validation of a case definition for osteoporosis disease surveillance

2010

View full text Add to dashboard Cite

show abstract

Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations: Application to Florida in 2000 through 2025

Abstract: This disease-modeling approach generates detailed information on the current and future cost burden of osteoporosis for an individual state population. Predictions based on this methodology may enable health-policy decisions that are tailored to local needs.

Cited by 44 publications

References 23 publications

Ökonomische Konzepte zur Erfassung der Krankheitskosten von Osteoporose: Österreich im internationalen Vergleich

Ökonomische Konzepte zur Erfassung der Krankheitskosten von Osteoporose: Österreich im internationalen Vergleich

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study

Validation of a case definition for osteoporosis disease surveillance

Contact Info

Product

Resources

About